3 replies to this topic

[scuba]

  Discontinuation of Sprycel or Tasigna in CML: Interim report if the STOP second Generation TKI study. http://www.bloodjour...so-checked=true

Summary:

 

A landmark analysis demonstrated that loss of MR4.5 3 months after stopping TKI was predictive of failure to maintain MMR later on. During the treatment-free phase, no progression toward advanced phase CML occurred and all relapsing patients regained MMR and MR4.5 after restarting therapy. To conclude, discontinuation of 1st or subsequent line 2G-TKI yields promising TFR rates without safety concerns. Further research is encouraged to better define conditions that will offer patients highest chances to remain free from 2G-TKI therapy.

[gerry]

Am I reading this correctly

A landmark analysis demonstrated that loss of MR4.5 3 months after stopping TKI was predictive of failure to maintain MMR later on.

 

They are saying that if people lose MR4.5 in the 3 months, they will most likely lose MMR later on?

If that is correct, then is it the fact that they tried cessation, or would this have occurred anyway, can't be the second option as that would mean we would have a lot of people losing response.

[scuba]

No...You are not reading it correctly.

They are referring to cessation failure. If after 3 months, a cessation patient loses MR4.5 (i.e. PCRU), then their ability to stay below MMR would likely be difficult as well. Loss of PCRU after 3 months was "predictive" that they will likely lose MMR later on. 

[gerry]

Thanks scuba,

I thought it was odd the way I was reading it.